Q-omics provides the consensus-scored SP3 profile across patient tissues and cancer cell-line models. SP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SP3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SP3 RNA expression shows 21,349 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where SP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SP3 survival associations across molecular data types. SP3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SP3 RNA expression–survival associations across cancer types. High SP3 expression shows unfavorable associations in ACC and KIRP, but favorable associations in UCS, KIRC, SCLC and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SP3 RNA expression.
This table summarizes SP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SP3 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, KIRC, LIHC and LUAD. The HNSC box plot shows higher SP3 RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with SP3 in patient tissues and cancer cell lines. In patient samples, SP3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
